Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

In a phase II RAPIDE trial, researchers administered the antiviral TKM-130803 daily for up to seven days to patients with confirmed Ebola in Sierra Leone. Two patients died within 48 hours. Beyond that time point, nine died and only three survived

An experimental antiviral against Ebola virus (pictured) was tested as part of the RAPIDE clinical trial, but was quickly found not to be effective

Source  National Institute of Allergy and Infectious Diseases (NIAID)